However, at the population level, significant changes in CYP2C9, CYP2C19, CYP2D6 or CYP3A4 metabolising activity were not recorded during chemotherapy in this cohort of women with stage II or III BC (p > 0.05; Table 1). Here, CYP2C9 is linked to breast cancer.